Comprehensive Analysis of Survival Outcomes in Non–Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials
作者: Guillermo de VelascoRana R. McKayXun LinRaphel B. MoreiraRonit SimantovToni K. Choueiri
作者单位: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Medical Oncology, University Hospital 12 de Octubre, Madrid, Spain
3Pfizer Oncology, Pfizer Inc, La Jolla, CA
刊名: Clinical Genitourinary Cancer, 2017, Vol.15 (6), pp.652-660.e1
来源数据库: Elsevier Journal
DOI: 10.1016/j.clgc.2017.03.004
关键词: Chromophobe RCCPapillary RCCRare histologic subtypesRenal cell carcinomaTargeted therapies
英文摘要: Abstract(#br)Background(#br)Clinical data from patients with non–clear cell renal cell carcinoma (nccRCC) receiving targeted therapy are limited, and many clinical trials have excluded these patients from study entry. We sought to investigate the outcomes of patients with nccRCC treated in clinical trials in the modern era compared with the outcomes of patients with clear cell RCC (ccRCC).(#br)Patients and Methods(#br)We conducted a retrospective study of patients with metastatic RCC who had received targeted therapy in Pfizer-sponsored phase II and III clinical trials from 2003 to 2013. Associations between the histologic type and treatment outcome (overall survival [OS] and progression-free survival [PFS]) were assessed using the log-rank test on univariate analysis or the Wald χ 2 test...
全文获取路径: Elsevier  (合作)
影响因子:1.429 (2012)

  • Analysis 分析